Viral Vector and Plasmid DNA Manufacturing Market – Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Application (Cancer, Genetic Disorder, Infectious Disease, Others), By Region, & Competition, 2020-2030F

Market Overview

Global Viral Vector and Plasmid DNA Manufacturing Market was valued at USD 6.80 Billion in 2024 and is anticipated to witness an steady growth in the forecast period with a CAGR of 10.85% through 2030. Viral vector and plasmid DNA manufacturing are essential processes in biotechnology and biopharmaceutical industries, particularly for applications like gene therapy, vaccine production, and genetic engineering. These processes involve the production and purification of viral vectors and plasmid DNA, which serve as crucial tools for various applications in the field of molecular biology and medicine. Different types of viral vectors are used, such as adeno-associated viruses (AAVs), lentiviruses, retroviruses, and others. The choice depends on the specific application and target cells. Plasmid DNA (pDNA) is a circular, double-stranded DNA molecule found in bacteria. It is commonly used in biotechnology for various purposes, including the production of recombinant proteins, gene cloning, and as a vector for gene therapy. A significant driver for the market is the growing investment in gene therapy research and development. Both viral vectors and plasmid DNA are essential components in gene therapy products. The potential to develop novel treatments for genetic and rare diseases has attracted substantial funding from both public and private sectors.

Ongoing advancements in biotechnology, including gene editing techniques like CRISPR-Cas9, have expanded the possibilities for gene therapy. This has driven the need for efficient and safe delivery systems, which viral vectors and plasmid DNA provide. The success of several gene therapies in clinical trials and their subsequent approvals by regulatory agencies, such as the FDA and EMA, have boosted confidence in the field. These successes encourage further investment and development in viral vectors and plasmid DNA. Gene therapies offer the potential for highly targeted treatments, which can minimize side effects and improve patient outcomes. This targeted approach is particularly attractive for cancer treatments and other complex diseases.

Key Market Drivers

Growing Investment in Biopharmaceutical R&D

As biopharmaceutical companies increase their R&D budgets, there is a clear strategic focus on cutting-edge therapies, particularly gene therapies, cell therapies, and DNA-based vaccines. In 2023, the top 20 global pharmaceutical companies among them Swiss giants Novartis and Roche collectively invested USD 145 billion in research and development, marking a 4.5% year-over-year increase. This rise underscores a sustained strategic focus on innovation-driven growth, with significant capital being allocated to pipeline expansion, next-generation therapies, and advanced biotechnologies. These therapies rely heavily on viral vectors (such as AAV, lentivirus) and plasmid DNA as delivery systems for therapeutic genetic material. With more R&D dollars flowing into this space, the number of research programs and preclinical studies increases significantly. This directly boosts demand for high-quality vectors and plasmids for experimental and clinical use. Manufacturers and suppliers of viral vectors and plasmid DNA experience a rise in order volumes, contract development opportunities, and long-term strategic partnerships.

As of January 2024, the Pharma projects database reported the addition of 5,428 new drug candidates in 2023, up from 5,082 in the previous year a clear indicator of intensified R&D activity across diverse therapeutic areas. After factoring in 3,895 drug exits due to discontinuation, regulatory setbacks, or successful approvals the net increase in the global development pipeline stood at 1,533 assets. This notable expansion highlights the industry's sustained momentum in innovation and its strategic commitment to replenishing and advancing pipelines in a competitive, high-stakes environment. R&D investment often translates into a broader pipeline of candidates entering clinical trials, many of which involve gene-modified therapies. Each clinical trial, especially in later stages, requires substantial quantities of GMP-grade viral vectors and plasmid DNA. As clinical trials scale up, biopharmaceutical companies must secure reliable and compliant manufacturing partners, fueling growth in the upstream production market. This trend drives expansion in both capacity and capabilities among contract manufacturing organizations (CMOs) and in-house bioproduction teams. With increased funding, biopharma companies are looking to optimize time-to-market and operational efficiency. Many are choosing to outsource vector and plasmid production to Contract Development and Manufacturing Organizations (CDMOs) rather than investing in costly in-house infrastructure. CDMOs with specialized expertise, scalable facilities, and regulatory know-how are seeing increased demand and forming long-term strategic partnerships. Outsourcing trends significantly contribute to the expansion of the global vector and plasmid DNA manufacturing ecosystem.

Increasing Prevalence of Chronic and Genetic Diseases

Chronic illnesses such as cancer, cardiovascular disease, neurological disorders, and autoimmune conditions are on the rise globally. In 2021, noncommunicable diseases (NCDs) accounted for at least 43 million deaths, representing 75% of all non-pandemic-related mortality worldwide. Alarmingly, 18 million of these deaths occurred in individuals under the age of 70, with 82% of such premature fatalities concentrated in low- and middle-income countries (LMICs). Overall, 73% of total NCD-related deaths were reported in LMICs, underscoring the disproportionate impact of chronic diseases on healthcare systems and populations with limited access to early diagnosis, treatment, and long-term care infrastructure. At the same time, there is growing awareness and improved diagnosis of inherited genetic disorders, many of which previously went undetected. Traditional treatment options are often limited, ineffective, or palliative. This has created a significant unmet need for curative or disease-modifying therapies, leading to increased demand for innovative treatments like gene and cell therapies, which rely on viral vectors and plasmid DNA. As healthcare systems prioritize long-term and more effective treatment strategies, there is growing demand for the core components that make these therapies possible specifically, high-quality viral vectors and plasmids. Gene therapy is uniquely positioned to address many previously untreatable or poorly managed genetic conditions, such as spinal muscular atrophy (SMA), hemophilia, Duchenne muscular dystrophy, and certain forms of inherited blindness. These therapies often require viral vectors (e.g., AAV, lentivirus) to deliver corrected or functional genes to a patient’s cells, and plasmid DNA to support the manufacturing process of those vectors. As more gene therapies targeting genetic diseases enter clinical trials or gain regulatory approval, manufacturers are seeing a sharp increase in demand for clinical- and commercial-grade vectors and plasmids.

Chronic diseases are increasingly being treated through precision medicine treatments tailored to an individual’s genetic profile. These personalized approaches often involve genetic modification or immune system engineering (such as CAR-T therapies), which rely heavily on plasmid DNA and viral vectors. Precision treatments require a customized or highly specific viral vector platform for each patient or patient group, creating demand for flexible, scalable manufacturing solutions. Companies with the capacity to provide modular, small-batch vector production or adaptable plasmid DNA synthesis are poised for strong growth in this area. Despite progress in genetic testing technologies, particularly whole exome and whole genome sequencing, a large share of patients with rare genetic disorders still goes undiagnosed. Current methods deliver an average diagnostic yield of only 30% to 42%, highlighting the ongoing limitations in uncovering the full spectrum of genetic mutations and the complexity of rare disease diagnosis. Thanks to advances in genomics and next-generation sequencing (NGS), more patients are being diagnosed with rare and ultra-rare genetic disorders, many of which have no existing therapies. Drug developers are prioritizing these orphan indications due to both the medical need and the regulatory and commercial incentives attached (such as market exclusivity and fast-track approvals). Each rare disease therapy requires specialized viral vector and plasmid DNA production, expanding the scope and diversity of demand in the manufacturing market.

Download Free Sample Report

Key Market Challenges

Costs and Pricing Pressures

Viral vector and plasmid DNA manufacturing processes can be complex, involving multiple steps and the use of specialized equipment and materials. These processes can be costly to establish and operate, leading to higher production costs. As gene therapies progress from research and development to commercial production, companies face the challenge of scaling up manufacturing processes. Achieving economies of scale while maintaining product quality is a delicate balance that impacts costs. Meeting stringent regulatory requirements for gene therapy products adds additional costs to manufacturing. Companies must invest in quality control, documentation, and compliance measures, which can be resource intensive. Ensuring the safety and efficacy of viral vectors and plasmid DNA products requires rigorous quality control and assurance processes. These processes can increase production costs, especially when addressing deviations or maintaining consistent quality. Building and maintaining state-of-the-art manufacturing facilities and cleanrooms compliant with Good Manufacturing Practices (GMP) standards is a significant upfront investment that can lead to cost pressures. The cost of raw materials, such as cell culture media, growth factors, and purification reagents, can impact overall manufacturing costs. Supply chain disruptions or fluctuations in raw material prices can increase these costs. Proper disposal of waste materials generated during manufacturing, including biological waste and hazardous materials, can be expensive and regulated.

Ethical and Societal Considerations

The ability to modify genes raises concerns about the potential for genetic enhancement and the creation of designer babies. Ethical debates revolve around the boundaries of gene editing and the implications for future generations. Ensuring that patients fully understand the risks and benefits of gene therapy is crucial. Obtaining informed consent from patients and, in some cases, their families or guardians, can be challenging, especially when dealing with vulnerable populations. There are concerns about equitable access to gene therapies. High costs can limit access to these treatments, potentially exacerbating health disparities. Ensuring affordability and accessibility for all patients is an ethical imperative. Gene therapies are relatively new, and their long-term safety and efficacy are not always well-understood.

Ethical considerations include the need for ongoing monitoring and the obligation to report adverse events. Editing the germline (sperm and egg cells) raises significant ethical questions. Permanent genetic changes made to the germline can be passed on to future generations, potentially altering the human gene pool. Obtaining informed consent for germline editing is particularly complex, as the implications extend to descendants who cannot provide consent. Global discussions are ongoing to establish guidelines and regulations for such interventions. Gene editing techniques can sometimes have unintended "off-target" effects, potentially causing harm. Ethical considerations include the need to minimize off-target effects and disclose any risks to patients.

Key Market Trends

Cell and Gene Therapy Ecosystem Development

Collaboration among academic institutions, research organizations, and biopharmaceutical companies is crucial for advancing cell and gene therapy technologies. These partnerships enable the exchange of knowledge, expertise, and resources, accelerating the development of innovative therapies. Many countries have established specialized research centers and institutes dedicated to cell and gene therapy research. These centers serve as hubs for cutting-edge research and provide a nurturing environment for scientists and innovators. Biotechnology clusters or hubs, often located in regions with a strong biotech presence, foster innovation, collaboration, and investment in cell and gene therapy. Examples include the Boston-Cambridge area in the United States and the Golden Triangle in the United Kingdom. Governments and private entities are providing funding and grants to support cell and gene therapy research and development.

These initiatives help attract top talent and stimulate innovation in the field. Regulatory agencies are actively engaged in shaping policies and pathways for cell and gene therapies. They provide guidance, expedited review processes, and incentives to facilitate product development and approvals. Investments in manufacturing facilities and infrastructure that meet Good Manufacturing Practices (GMP) standards are essential. This includes the construction of specialized cell and gene therapy manufacturing plants. Patient advocacy organizations and support groups play a vital role in advancing cell and gene therapies. They raise awareness, advocate for patients' needs, and provide valuable insights to researchers and developers. Venture capital firms and investors are increasingly interested in funding cell and gene therapy startups. This investment activity drives innovation and entrepreneurship in the ecosystem.

Segmental Insights

Product Type Insights

Based on the category of Product Type, Plasmid DNA segment emerged as the fastest growing segment in the Global Viral Vector and Plasmid DNA Manufacturing Market. Plasmid DNA is used in various applications beyond gene therapy, including vaccine development, protein expression, and research purposes. This versatility allows it to have a broader market reach and more diverse customer base compared to viral vectors, which are primarily used in gene therapy. Plasmid DNA plays a crucial role in the development of DNA-based vaccines, which have gained attention due to their potential in preventing infectious diseases. The COVID-19 pandemic led to increased demand for DNA vaccines, boosting the plasmid DNA manufacturing market. Many biopharmaceutical and biotech companies already have established infrastructure and expertise for plasmid DNA production, making it a convenient choice for in-house research and development.

Download Free Sample Report

Regional Insights

Based on region, North America region emerged as the largest market in the Global Viral Vector and Plasmid DNA Manufacturing Market in 2024. North America, particularly the United States, has a well-developed and mature biopharmaceutical industry. The region is home to numerous biotechnology and pharmaceutical companies with extensive experience in research, development, and manufacturing of biologics, including viral vectors and plasmid DNA. North America has been at the forefront of gene therapy research and development. The United States has seen significant investment and progress in the field, leading to a higher number of clinical trials and commercialization efforts involving viral vectors and plasmid DNA. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have provided clear pathways and guidance for the development and approval of gene therapies. This regulatory clarity has attracted investments and encouraged companies to pursue clinical development and manufacturing activities in the region.

Recent Developments

• In June 2024, ProBio Inc., a New Jersey-based CDMO, has announced the opening of its new, state-of-the-art manufacturing facility in Hopewell, New Jersey, marking a major expansion of its plasmid DNA and viral vector production capabilities. Designed to serve as the company’s North American operational hub, the facility significantly strengthens ProBio’s capacity to support the development and manufacturing of advanced cell and gene therapies. This strategic investment underscores ProBio’s commitment to meeting growing demand for high-quality genetic materials across the North American biotherapeutics market.
• In May 2024, Charles River Laboratories International, Inc. (NYSE: CRL) has unveiled its Modular and Fast Track viral vector technology transfer frameworks, aimed at significantly accelerating the transfer of manufacturing processes to its Maryland-based viral vector Center of Excellence. Leveraging decades of CDMO expertise in viral vector development, the company has developed a structured, time-efficient approach that enables seamless tech transfer in as little as nine months. This initiative is designed to support clients in advancing gene therapy programs with greater speed, reliability, and manufacturing readiness.
• In November 2023, SK Pharmteco Co., the contract development and manufacturing arm of South Korea’s SK Group, has launched two proprietary viral vector platforms designed to streamline the production of advanced cell and gene therapies (CGTs). These newly introduced platforms are engineered to optimize manufacturing efficiency, enabling faster turnaround times and cost-effective scalability—key advantages for biopharma developers navigating the complex CGT landscape. This strategic innovation reinforces SK Pharmteco’s position as a competitive player in the global viral vector manufacturing market.
• In October 2023, AGC Biologics has finalized the expansion of its Heidelberg, Germany facility, introducing a new plasmid DNA (pDNA) and messenger RNA (mRNA) production line. This strategic upgrade significantly enhances the site’s capacity to deliver high-quality and GMP-grade plasmid material, while also broadening its end-to-end mRNA manufacturing capabilities. The new line is equipped with advanced single-use technologies, enabling parallel processing of multiple projects with greater operational agility, shorter lead times, and accelerated turnaround. This expansion positions AGC Biologics to meet rising demand from developers seeking reliable, scalable solutions for pDNA and mRNA-based therapeutics.

Key Market Players

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

Report Scope:

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•  Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

o   Plasmid DNA

o   Viral Vector

o   Non-viral Vector

•  Viral Vector and Plasmid DNA Manufacturing Market, By Application:

o   Cancer

o   Genetic Disorder

o   Infectious Disease

o   Other

• Viral Vector and Plasmid DNA Manufacturing Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Available Customizations:

Global Viral Vector and Plasmid DNA Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Viral Vector and Plasmid DNA Manufacturing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com